J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.

earnings report

Biopharmaceutical companies can't talk business strategy with investors for long these days without addressing the issue of US drug pricing and healthcare reform. That was the case during Johnson & Johnson’s commercial overview presentation Sept. 13, where Vice Chairman Joaquin Duato assured investors the diversified pharma is well positioned to absorb changes, whatever shape they take.

J&J executives stressed that the company derives all of its growth from volume, not from price increases. Duato boasted of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip